Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Shares Issued (2022 - 2025)

Axsome Therapeutics' Shares Issued history spans 4 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Shares Issued fell 65.44% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $67.9 million, up 66.5%, while the annual FY2025 figure was $67.9 million, 66.5% up from the prior year.
  • Shares Issued for Q4 2025 was $5.7 million at Axsome Therapeutics, down from $9.9 million in the prior quarter.
  • Across five years, Shares Issued topped out at $240.3 million in Q4 2022 and bottomed at $176000.0 in Q2 2022.
  • The 4-year median for Shares Issued is $9.9 million (2025), against an average of $39.9 million.
  • The largest annual shift saw Shares Issued surged 119956.82% in 2023 before it plummeted 95.85% in 2024.
  • A 4-year view of Shares Issued shows it stood at $240.3 million in 2022, then tumbled by 85.96% to $33.8 million in 2023, then tumbled by 51.35% to $16.4 million in 2024, then crashed by 65.44% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Shares Issued are $5.7 million (Q4 2025), $9.9 million (Q3 2025), and $35.2 million (Q2 2025).